中国生命科学与医疗行业调研结果：2024年行业现状与展望

ChinaLSHCIndustrySurvey2024StateofIndustryinChina ChinaLifeSciences&HealthCareTeam March2024 Content Framework Results–Questions&Deep-dive •ChinaLSHCBusinessOutlook&Considerations •RegulatoryandDigitalRevolution •NewBusinessOpportunities&Challenges Concludinginsights Appendix ©2024.Forinformation,contactDeloitteChina.ChinaLifeSciences&HealthCareIndustry2024SurveyResults2 •Surveyperiod:15January2024to9February2024 •EngagedChina-basedLifeSciences&HealthCare(LSHC)sectoroperatorsandinvestors:124respondents ChinaLSHCIndustry2024OutlookSurvey–Framework 39% 5% Company 39% SOEPOE 19% 35% Chairman/CEO ManagementC-suiteLevel 20% 2% 8%1% Industry PharmaMedicalDevices HealthcareServices Type 18% JV WOFE Level 46% OtherManagement Level Veryconsistentfrom2023 Sector 69% Distributor/Retailer Others Veryconsistentfrom2023 Slightlymoredomesticcompanies,asPOE&SOEthisyearare44%, in2023just35% 15% No.of Lessthan5,000 38% 25% 2023 LessthanRMB100millionRMB100millionto1billion Similarsizerespondentswith42having>5kemployees,in2023therewere50respondents 19% Employees 66% 5,000to10,000 Morethan10,000 RevenueSize 19% 18% RMB1billionto5billionMorethanRMB5billion Alignedwithsize,largercompanieswithrevenues>1Bare71companies,in2023thatsegmenttotaled75 Note:SOE–State-ownedEnterprise;POE–Private-ownedEnterprise;JV–JointVenture;WOFE–WollyForeign-ownedEnterprises ©2024.Forinformation,contactDeloitteChina.ChinaLifeSciences&HealthCareIndustry2024SurveyResults3 ChinaLSHCBusiness Outlook&Considerations ©2024.Forinformation,contactDeloitteChina.ChinaLifeSciences&HealthCareIndustry2024SurveyResults4 OverallBusinessOutlook&Considerations #1.Howdidyourcompanyperform(topline)in2023FY? AllLargecosSOE&POEWOFELifeScience 50% 8% 28% 32% 13% 31% 32% 28% 41% 14% 22% 11% Annualfinancialperformanceis 28% 33% 28% betterthanplanned 28% 37% 47% 41% 29% 50% 42% 56% 32% 53% 44% 38% 27% 16% 31% Annualfinancialperformanceisinlinewithplans 7% 34% 31% 52% 31% 18% 46% 40% 19% 45% 17% 61% 41% 34% 41% Annualfinancialperformanceisworsethanplans 2024Survey 2023Survey 2022Survey KeyInsights •Overall:while60%saw2023resultsasplannedorbetter,asignificantimprovementsfrompreviousyear(~50%)yet40%hadaworsethanplanned performancein2023–showingthatexpectationswerehighbutfailedtomaterialize. •LargeandForeigncompanies(WOFE)aregainingbetterbusinessoutcomein2023FY–probablyresultingfromamorecautiousapproachtopastyear.Especiallyforforeignbusinesses,as50%reportedabetterperformancethanplanned •Localcompanies(SOE/POE)seemedtohavehadhigherexpectationsfor2023–andwhichdidnotmaterialize. •Surprisingly,lifesciencecompanies(86/124)arereportingfor73%eitherbeloworaboveexpectations2023results–showingthat2023wasfullofsurprises. Note:Largecos–companywith2023revenueexceedRMB1billion;SOE–State-ownedEnterprise;POE–Private-ownedEnterprise;JV–JointVenture;WOFE–WollyForeign-ownedEnterprises;thereareafewresponsesareunknownforthe2022surveythereforethetotalsumof2022percentagemaynotbe100% ©2024.Forinformation,contactDeloitteChina.ChinaLifeSciences&HealthCareIndustry2024SurveyResults5 OverallBusinessOutlook&Considerations Largecos SOE&POE WOFE C-level LifeScience ① ① ① ① ① ② ③ ② ② ② ④ ② ⑤ ③ ③ ⑤ ⑤ ③ ④ ⑤ ③ ④ ④ ⑤ ④ ⑥ ⑥ ⑥ ⑥ ⑥ ⑦ ⑦ ⑦ ⑦ ⑦ #2.Your2023businessperformancewasmainlyimpactedby… All 81% 57% 56% 10% 11% 21% 23% 38% 27% 40% 50% 40% 63% EffectsfromtheVBPpoliciesorNRDLinclusion AchievingnewproductlaunchesinChinaIncreasedbusinessdevelopmentefforts(e.g.globalor localdrivendeals) Partneringwithlocal/domesticorganizationstoreachafastermarketpenetration 2024Survey 2023Survey KeyInsights ChangesinHospitalaccessduringtheyearLocalizingyoursupplychaininChinaIncreaseddirectpatientengagement •Pricingandtheoveralleconomicvaluecycleremainthetopimpactfactorsforallstakeholderssinceourlastyear’sstudy •Successfulproductlaunchhasrisenofimportance,asthisisthenewbattlefieldtostayrelevantandalsogrowtopline •Enhancedlocalizedbusinessdevelopmenteffortsandallocatedresources,togetherwithfindingabettermarketaccessthroughpartneringmodelsarecitedbynearlyhalfoftherespondents.Especiallyforeigncompaniesarekeentoexploresuchmodels. •Interestingly,thelocalizationprogramsforexistingsupplychainsremainthesamefromprioryear.Carbonemissionaswellasglobalproduction capacitiesandlocalmarketvolumesareyettoeventuallygeneratechanges. Note:Largecos–companywith2023revenueexceedRMB1billion;SOE–State-ownedEnterprise;POE–Private-ownedEnterprise;JV–JointVenture;WOFE–WollyForeign-ownedEnterprises ©2024.Forinformation,contactDeloitteChina.ChinaLifeSciences&HealthCareIndustry2024SurveyResults6 OverallBusinessOutlook&Considerations #3.Withinyourorganizational&businessmodelwhicharethekeychangesimplementedin2023? All 83% 83% 59% 42% 15% 9% 26% 27% 35% 49% 50% 53% 64% 72% 56% 79% Marketingandsalesteamshavebeenadjustedasaresultofpoliciesandregulatory HighImportance impact MarketingandsalesteamshavebeenadjustedtoreflectnewchannelsGovernmentaffairsandrelationshavebecomemoreimportantthanbeforeR&DactivitiesinChi